Here are four things to know:
1. The Senators have requested documents and information from four pharmaceutical companies — Valeant Pharmaceuticals, Turing Pharmaceuticals, Retrophin and Rodelis Therapeutics.
2. The announcement follows a series of media reports on drug price increases after the acquisition or merger of pharmaceutical companies.
3. The Committee’s investigation will also focus on the FDA’s role in the drug approval process for generic drugs, the agency’s distribution protocols and, if necessary, its off-label regulatory regime.
4. The Senate Special Committee on Aging has tentatively scheduled an initial hearing on Dec. 9.
More articles on ASC issues:
18 statistics on ASC case volume
If healthcare providers don’t adopt digital technology, quality suffers — 7 survey highlights
10 statistics on clinical & office staff additions in the coming year
